The OFT alleges that GSK breached competition law to
delay rivals' generic copies of Seroxat, one of its most profitable drugs. See
BBC News report. "GlaxoSmithKline (GSK) has been accused of market "abuse"
by the consumer watchdog, the Office of Fair Trading (OFT). The
OFT alleges that the pharmaceutical giant paid rivals to delay the
release their own versions of GSK's Seroxat treatment. Alpharma, Generics UK and
Norton Healthcare all received money not to enter the market with their copies
of Seroxat, it said."
We must not be surprised at GlaxoSmithKline being accused of
nefarious activities. You can read here of several more breaches of the Law by
GSK with regard to the antidepressant, Seroxat, and other pharmaceutical
junk that GSK manufactures. Some further examples of its criminality can be found on this page.
var sc_project=1725605;
var sc_invisible=0;
var sc_partition=16;
var sc_security="acf71b9a";